The investigation specifically examines whether ADMA’s leadership prioritized artificial growth targets over their fiduciary responsibilities to shareholders. ADMA, headquartered in Ramsey, New Jersey, specializes in intravenous immune globulin therapies used to treat primary humoral immunodeficiency. By allegedly flooding distribution channels with inventory, the company may have misrepresented its true financial health during a period where demand for its core product was reportedly softening.
Berger Montague Probes ADMA Biologics Over Potential Channel-Stuffing
Philadelphia-based law firm Berger Montague has launched an investigation into the board of directors at ADMA Biologics, scrutinizing whether the company employed deceptive sales tactics to inflate revenue. The inquiry centers on allegations of channel-stuffing, a practice intended to mask declining demand for the firm’s flagship immune therapy, ASCENIV.
Investors holding stock in the biopharmaceutical firm are now being encouraged to review their positions and contact the firm’s legal representatives, Andrew Abramowitz or Caitlin Adorni. Berger Montague, a prominent player in class-action litigation, seeks to determine if these sales practices caused financial harm to the investor base. The firm has a history of pursuing complex securities litigation, having secured significant judgments in recent years.
Comments (0)
No comments yet. Be the first!